Market Overview

Tempest Therapeutics Names Dr. Ginna Laport CMO


--Dr. Alicia Levey promoted to CBO--

Tempest Therapeutics Inc., a development-stage biotechnology company
advancing small molecules that modulate anti-tumor immunity pathways,
today announced that Ginna Laport, M.D., joined the company as Chief
Medical Officer. Dr. Laport brings significant expertise in hematology,
oncology and clinical drug development, and will lead the evaluation and
clinical development of Tempest's portfolio of novel first-in-class drug
candidates in patients with advanced malignancies.

"We are very excited to welcome Ginna to the Tempest team. She has an
impressive academic and biotech pedigree together with a track record of
advancing multiple modalities of cancer therapeutics. Ginna will be
integral in the transition of Tempest into a clinical-stage
biotechnology company in 2019," said CEO Tom Dubensky, Ph.D.

Prior to joining Tempest, Dr. Laport served as vice president of
clinical development at Corvus Pharmaceuticals, where she led the
clinical development of small molecules and antibodies targeting the
adenosine pathway to treat advanced solid tumors. Additionally, Dr.
Laport was a member of the Executive Committee and oversaw clinical
development and operations.

Before Corvus, Dr. Laport was faculty in the Stanford University School
of Medicine, most recently as professor of medicine in the Division of
Blood and Marrow Transplantation (BMT). Her research focused on adoptive
immunotherapies for malignant diseases and she served as director of
clinical research in the BMT Division and as an associate director of
the Stanford Cancer Institute. Prior to Stanford, Dr. Laport was an
assistant professor in hematology/oncology at the University of
Pennsylvania. Dr. Laport served on the FDA's Oncologic Drugs Advisory
Committee (ODAC), was national chair of the NIH-sponsored BMT Clinical
Trials Network that directs multicenter clinical trials, and has
co-authored over 80 publications.

Dr. Laport received her M.D. from the University of Texas-Houston and a
B.A. from Baylor University. She completed her internal medicine
residency and fellowship in hematology/oncology at The University of

In addition, Tempest has promoted Dr. Alicia Levey to Chief Business
Officer. Dr. Levey previously was Tempest's VP of business development
and strategy. Prior to Tempest, she was VP of business development at
Inception Sciences, a small molecule drug discovery company formed in
collaboration with Versant Ventures, a global venture capital firm
focused primarily on early stage investing and biotechnology company

Dr. Levey is an operating principal at Versant where she has led the
diligence on multiple deals including several that have been acquired or
are now public. She holds a Ph.D. from the Stanford University School of

"We are delighted to have Alicia in the CBO role," said Dr. Dubensky.
"She has been a critical component in establishing Tempest and has a
deep track record of successful business development."

About Tempest Therapeutics

Tempest Therapeutics is a development-stage biotechnology company
advancing small molecules that modulate anti-tumor immunity pathways.
The company has a balanced and deep pipeline consisting of
first-in-class and potential best-in-class small molecule therapeutics
that modulate distinct immune response pathways relevant to mounting an
effective anti-tumor response. Tempest's backers include Versant
Ventures, F-Prime Capital, Quan Capital, Lilly Asia Ventures, Foresite
Capital and Eight Roads Ventures.

View Comments and Join the Discussion!